ClinicalTrials.gg
RecruitingNCT06452316Updated Aug 13, 2026

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

A Phase 1 interventional study of CSB-001 Ophthalmic Solution 0.1% in Limbal Stem Cell Deficiency, sponsored by Claris Biotherapeutics, Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Claris Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).

02

Conditions studied

  • Limbal Stem Cell Deficiency
03

In context

Limbal Stem Cell Deficiency

38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.

This study's planned enrollment of 75 is above the median of 20 across 23 interventional studies indexed under Limbal Stem Cell Deficiency.

Browse Limbal Stem Cell Deficiency studies →

Lead sponsor

Claris Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an area of the central 5 mm zone of cornea affected, presence of at least one clinical sign observed by slit-lamp examination with white light and/or cobalt blue light, fluorescein, and a Wratten filter, and at least one clinical sign observed with AS-OCT.
  • If dosing with Acthar at time of Screening Visit, must have a history of stable dosing for approximately 8 weeks, plan to maintain the same Acthar treatment dose and regimen, and have demonstrated little to no improvement in severity of LSCD.
  • Sponsor written confirmation of qualifying LSCD diagnosis.
  • Inflammation associated with LSCD or other non-infectious inflammation that will not interfere with subject's participation.

Exclusion criteria

Exclusion Criteria:

  • Any active ocular infection (bacterial, viral, fungal, or protozoan) in either eye.
  • Ocular surgery within 30 days of Day 0 where investigator assesses that healing is not considered complete/stable.
  • Planned ocular surgery on or before Week 20 visit.
  • Presence or history of any ocular or systemic disorder, condition, or procedure that might hinder the efficacy of the study treatment or its evaluation, or could interfere with the interpretation of study results, in the opinion of the investigator.

Note: Other inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Control

    Period I: Subjects will be observed (non-interventional) for 20 weeks. Period II: Subjects will be dosed one drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s) separated by \>30 days and \<40 days (dosing holiday) followed by observation (non-interventional) to Week 48. Period III: Subjects may elect to participate in the Observation Extension Phase (non-interventional) for an additional 36 months to Week 144.

    Biological: CSB-001 Ophthalmic Solution 0.1%

  • Experimental
    CSB-001 QID

    Period I: Subjects will be dosed one drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s) separated by \>30 days and \<40 days (dosing holiday) followed by observation (non-interventional) to Week 20. Period II: Subject will be observed (non-interventional) for 28 weeks to Week 48. Period III: Subjects may elect to participate in the Observation Extension Phase (non-interventional) for an additional 36 months to Week 144.

    Biological: CSB-001 Ophthalmic Solution 0.1%

Interventions

  • BiologicalCSB-001Studies of CSB-001CSB-001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

06

What researchers measure

Primary outcomes

  1. Safety as Assessed by Adverse Event Reporting

    Incidence of ocular and systemic adverse events

    Time frame: Day 0 through Week 144

  2. Safety as Assessed by Slit-lamp Biomicroscopy

    Change from baseline in slit-lamp parameters

    Time frame: Day 0 through Week 144

  3. Safety as Assessed by Best-corrected Distance LogMAR Visual Acuity

    Change from baseline using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart

    Time frame: Day 0 through Week 144

Secondary outcomes

  1. Efficacy as Assessed by Change in Stage of LSCD

    Change from baseline in LSCD signs based on imaging (white light, blue light with fluorescein and Wratten filter, and AS-OCT)

    Time frame: Day 0 through Week 144

  2. Efficacy as Assessed by Change in Best-corrected Distance LogMAR Visual Acuity

    Visual acuity measured using the EDTRS visual acuity chart

    Time frame: Day 0 through Week 144

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 11, 2024
StartActual
May 15, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06452316
Lead sponsor
Claris Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
May 15, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Central Operations Representative
Contact
clinicaltrials@clarisbio.com
949-354-1299

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CSB-001

Start the discussion